Fisher Asset Management LLC Has $14.29 Million Stock Holdings in Insulet Corporation $PODD

Fisher Asset Management LLC increased its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 38.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 46,273 shares of the medical instruments supplier’s stock after acquiring an additional 12,754 shares during the period. Fisher Asset Management LLC owned about 0.07% of Insulet worth $14,286,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. True Wealth Design LLC lifted its stake in Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 72 shares during the period. Golden State Wealth Management LLC raised its holdings in shares of Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 43 shares during the period. Quent Capital LLC bought a new position in shares of Insulet during the 3rd quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in Insulet in the 2nd quarter valued at $51,000.

Insider Activity

In other news, Director Michael R. Minogue purchased 2,030 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.39% of the stock is owned by company insiders.

Insulet Price Performance

Shares of PODD stock opened at $242.89 on Thursday. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The firm’s 50 day moving average is $265.50 and its 200-day moving average is $301.62. The firm has a market capitalization of $17.10 billion, a price-to-earnings ratio of 69.40, a PEG ratio of 1.44 and a beta of 1.42. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business had revenue of $783.80 million during the quarter, compared to analyst estimates of $768.31 million. During the same quarter last year, the business posted $1.15 earnings per share. Insulet’s revenue for the quarter was up 31.2% compared to the same quarter last year. Sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on PODD shares. Canaccord Genuity Group dropped their price objective on Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. Oppenheimer lowered their target price on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Royal Bank Of Canada lifted their price target on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Truist Financial decreased their price objective on shares of Insulet from $390.00 to $360.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus price target of $354.57.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.